BioCentury
ARTICLE | Clinical News

Arbaclofen placarbil: SPA received

May 2, 2011 7:00 AM UTC

XenoPort received an SPA from FDA for a planned double-blind, placebo-controlled, U.S. Phase III trial to evaluate twice-daily 15, 30 and 45 mg arbaclofen placarbil for 13 weeks in about 200 patients....